Larotrectinib Alternatives Compared
| Larotrectinib | Pembrolizumab | Keytruda (pembrolizumab) |
|
|---|
| Larotrectinib | Pembrolizumab | Keytruda (pembrolizumab) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Solid Tumors. Larotrectinib may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Bladder Cancer, Cervical Cancer, Breast Cancer, Biliary Tract Tumor, Colorectal Cancer, Endometrial Cancer, Esophageal Carcinoma, Gastric Cancer, Head and Neck Cancer, Hepatocellular... View more |
Prescription only
Keytruda is an immunotherapy treatment called a checkpoint inhibitor that helps your immune system fight cancer and is used to treat many different types of cancer in adults and children including... View more |
Related suggestions Solid Tumors
|
|||||||
| More about Larotrectinib | More about Pembrolizumab | More about Keytruda (pembrolizumab) | ||||||||
| Ratings & Reviews | ||||||||||
|
Larotrectinib has an average rating of 9.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Pembrolizumab has an average rating of 5.3 out of 10 from a total of 287 ratings on Drugs.com. 44% of reviewers reported a positive effect, while 44% reported a negative effect. |
Keytruda has an average rating of 5.0 out of 10 from a total of 259 ratings on Drugs.com. 41% of reviewers reported a positive effect, while 47% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||
|
View all Larotrectinib side effects |
View all Pembrolizumab side effects |
View all Keytruda side effects |
||||||||
| Drug Class | ||||||||||
| Generic Availability | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Keytruda prices |
||||||||
| Dosage Forms | ||||||||||
|
N/A |
N/A |
|
||||||||
| Brand Names | ||||||||||
| Vitrakvi | Keytruda |
N/A |
||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||
|
2.9 hours |
624 hours |
624 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 515 drugs are known to interact with Larotrectinib:
|
A total of 596 drugs are known to interact with Pembrolizumab:
|
A total of 596 drugs are known to interact with Keytruda:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
November 26, 2018 |
N/A |
N/A |
||||||||
| WADA Class View classifications | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient Resources | ||||||||||
| Professional Resources | ||||||||||
| Related Treatment Guide | ||||||||||
|
|
|||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.